Somatostatin for Uveitic Cystoid Macular Edema (CME)

Ocul Immunol Inflamm. 2005 Dec;13(6):469-70. doi: 10.1080/09273940691001964.

Abstract

Purpose: To report the favorable response of bilateral recalcitrant uveitic cystoid macular edema (CME) to treatment with a somatostatin analog.

Methods: Medical ophthalmic history and the results of ophthalmic examinations were recorded. Fluorescein angiography (FA) studies were reviewed.

Results: A 52-year-old white female with intermediate uveitis developed bilateral recalcitrant CME. Treatment with subcutaneous injections of the somatostatin analog octreotide resulted in partial resolution of the CME and improvement of visual acuity.

Conclusions: Somatostatin may play a role in the treatment of CME secondary to uveitis.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Hormonal / administration & dosage
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Female
  • Fluorescein Angiography
  • Follow-Up Studies
  • Fundus Oculi
  • Humans
  • Injections, Subcutaneous
  • Macular Edema / diagnosis
  • Macular Edema / drug therapy*
  • Macular Edema / etiology
  • Middle Aged
  • Octreotide / administration & dosage
  • Octreotide / therapeutic use*
  • Somatostatin / analogs & derivatives*
  • Uveitis, Intermediate / complications*

Substances

  • Antineoplastic Agents, Hormonal
  • Somatostatin
  • Octreotide